| Epigenetics and DNA Methylation | Lifetime | 247 | CN 11 | 99.25 |
| Cancer-related gene regulation | Lifetime | 132 | CN 8 | 99.05 |
| Cancer-related molecular mechanisms research | Lifetime | 325 | CN 150 | 98.84 |
| RNA modifications and cancer | Lifetime | 400 | CN 41 | 99.13 |
| Ferroptosis and cancer prognosis | Lifetime | 142 | CN 60 | 97.98 |
| Histone Deacetylase Inhibitors Research | Lifetime | 141 | CN 6 | 98.48 |
| Gut microbiota and health | Lifetime | 655 | CN 71 | 97.89 |
| Ubiquitin and proteasome pathways | Lifetime | 545 | CN 46 | 97.64 |
| Peptidase Inhibition and Analysis | Lifetime | 960 | CN 31 | 97.08 |
| Cancer-related Molecular Pathways | Lifetime | 996 | CN 53 | 96.92 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | Lifetime | 769 | CN 11 | 96.55 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 647 | CN 31 | 95.37 |
| Sirtuins and Resveratrol in Medicine | Lifetime | 323 | CN 49 | 93.84 |
| Occupational and environmental lung diseases | Lifetime | 558 | CN 11 | 94.81 |
| FOXO transcription factor regulation | Lifetime | 588 | CN 110 | 81.11 |
| Epigenetics and DNA Methylation | 2021-2025 | 2 | CN 1 | 99.85 |
| Cancer-related gene regulation | 2021-2025 | 3 | CN 2 | 99.77 |
| RNA modifications and cancer | 2021-2025 | 18 | CN 12 | 99.78 |
| Gut microbiota and health | 2021-2025 | 84 | CN 43 | 99.03 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 15 | CN 2 | 98.98 |
| Cancer-related molecular mechanisms research | 2021-2025 | 146 | CN 109 | 98.60 |
| Immune cells in cancer | 2021-2025 | 105 | CN 63 | 97.40 |
| Ferroptosis and cancer prognosis | 2021-2025 | 129 | CN 101 | 97.67 |
| Ubiquitin and proteasome pathways | 2021-2025 | 95 | CN 42 | 95.09 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 200 | CN 90 | 94.82 |
| RNA Research and Splicing | 2021-2025 | 229 | CN 70 | 94.41 |
| Peptidase Inhibition and Analysis | 2021-2025 | 211 | CN 49 | 95.40 |
| Immune Cell Function and Interaction | 2021-2025 | 731 | CN 158 | 92.72 |
| MicroRNA in disease regulation | 2021-2025 | 670 | CN 404 | 93.25 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | 2021-2025 | 562 | CN 68 | 91.53 |
| Glycosylation and Glycoproteins Research | 2021-2025 | 508 | CN 126 | 86.95 |
| Tryptophan and brain disorders | 2021-2025 | 962 | CN 282 | 87.10 |
| Cancer Mechanisms and Therapy | 2021-2025 | 338 | CN 135 | 84.80 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 192 | CN 34 | 83.05 |
| Advanced Breast Cancer Therapies | 2021-2025 | 767 | CN 78 | 86.13 |
| Occupational and environmental lung diseases | 2021-2025 | 388 | CN 50 | 83.01 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 764 | CN 151 | 81.07 |
| Estrogen and related hormone effects | 2021-2025 | 544 | CN 52 | 78.51 |
| Galectins and Cancer Biology | 2021-2025 | 414 | CN 103 | 76.81 |
| Sirtuins and Resveratrol in Medicine | 2021-2025 | 319 | CN 89 | 73.91 |
| Cancer-related Molecular Pathways | 2021-2025 | 845 | CN 180 | 73.53 |
| Cell Adhesion Molecules Research | 2021-2025 | 825 | CN 107 | 70.61 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 323 | CN 52 | 68.67 |
| Microtubule and mitosis dynamics | 2021-2025 | 976 | CN 128 | 64.87 |
| Hippo pathway signaling and YAP/TAZ | 2021-2025 | 634 | CN 274 | 62.27 |
| Polyamine Metabolism and Applications | 2021-2025 | 623 | CN 273 | 57.94 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 989 | CN 361 | 55.59 |
| FOXO transcription factor regulation | 2021-2025 | 272 | CN 100 | 51.53 |
